« Back
Home /
Grazoprevir

Grazoprevir

Item no.	HY-15298-5mg
Manufacturer	MedChem Express
CASRN	1350514-68-9
Amount	5 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.94
Citations	[1]Summa V, et al. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob Agents Chemother. 2012 Aug;56(8):4161-7.\|[2]Harper S, et al. Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor. ACS Med Chem Lett. 2012 Mar 2;3(4):332-6.\|[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212. Antivir Res. 2019 Nov;171:104612.\|Antiviral Res. 2017 Mar;139:18-24. \|Antiviral Res. 2021 Dec 2;105224.\|bioRxiv. 2023 Feb 27.\|bioRxiv. 2023 Oct 26.\|bioRxiv. 2024 Dec 3:2024.11.26.625483.\|bioRxiv. 2024 Mar 12.\|Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.\|Cancer Immunol Res. 2021 Jun 30.\|Elife. 2020 Jun 9;9:e56469.\|J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Mar 15;1110-1111:15-24. \|J Gastroenterol. 2019 May;54(5):449-458. \|J Pharmaceut Biomed. 2020 Jan 30;178:112964.\|Nat Biotechnol. 2019 Oct;37(10):1209-1216.\|Nat Commun. 2020 Sep 4;11(1):4417.\|Nat Methods. 2018 Jul;15(7):519-522.\|Patent. US12065501.\|Patent. US20180346589A1.\|Patent. US20190010245A1.\|Patent. US20220025003A1.\|Pharmaceuticals. 2022 Feb 18;15(2):242.\|Research Square Preprint. 2024 Jan 23.\|Sci Rep. 2022 Jul 16;12(1):12197.\|Sci Rep. 2019 Apr 5;9(1):5722.\|Signal Transduct Target Ther. 2021 May 29;6(1):212.\|University of Glasgow. 2024 Mar.\|Cancer Cell. 2022 Aug 26;S1535-6108(22)00372-5.\|Cancer Cell. 2024 Nov 11;42(11):1955-1969.e7.
Smiles	COC1=CC2=C(N=C(CCCCC[C@@H]3C[C@H]3OC4=O)C(O[C@H]5CN(C([C@H](C(C)(C)C)N4)=O)[C@H](C(N[C@@]([C@@H]6C=C)(C6)C(NS(C7CC7)(=O)=O)=O)=O)C5)=N2)C=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	MK-5172
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Targets	HCV; HCV Protease; SARS-CoV
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	766.90
Product Description	Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively[1][2]. Grazoprevir inhibits SARS-CoV-2 3CLpro activity[3].
Manufacturer - Research Area	Infection
Solubility	DMSO : 50 mg/mL (ultrasonic)\|Ethanol : 66.67 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Metabolic Enzyme/Protease
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-15298-5mg-safety-datasheet.pdf